vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $34.1M, roughly 1.5× Karyopharm Therapeutics Inc.). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -299.9%, a 294.8% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -14.2%). Over the past eight quarters, READING INTERNATIONAL INC's revenue compounded faster (5.6% CAGR vs 1.4%).
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
KPTI vs RDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $50.3M |
| Net Profit | $-102.2M | $-2.6M |
| Gross Margin | — | — |
| Operating Margin | -52.4% | -1.9% |
| Net Margin | -299.9% | -5.1% |
| Revenue YoY | 11.6% | -14.2% |
| Net Profit YoY | -232.0% | -14.5% |
| EPS (diluted) | $-7.02 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $50.3M | ||
| Q3 25 | $44.0M | $52.2M | ||
| Q2 25 | $37.9M | $60.4M | ||
| Q1 25 | $30.0M | $40.2M | ||
| Q4 24 | $30.5M | $58.6M | ||
| Q3 24 | $38.8M | $60.1M | ||
| Q2 24 | $42.8M | $46.8M | ||
| Q1 24 | $33.1M | $45.1M |
| Q4 25 | $-102.2M | $-2.6M | ||
| Q3 25 | $-33.1M | $-4.2M | ||
| Q2 25 | $-37.3M | $-2.7M | ||
| Q1 25 | $-23.5M | $-4.8M | ||
| Q4 24 | $-30.8M | $-2.2M | ||
| Q3 24 | $-32.1M | $-7.0M | ||
| Q2 24 | $23.8M | $-12.8M | ||
| Q1 24 | $-37.4M | $-13.2M |
| Q4 25 | -52.4% | -1.9% | ||
| Q3 25 | -34.6% | -0.6% | ||
| Q2 25 | -64.3% | 4.8% | ||
| Q1 25 | -110.8% | -17.2% | ||
| Q4 24 | -102.4% | 2.6% | ||
| Q3 24 | -67.8% | -0.6% | ||
| Q2 24 | -65.7% | -16.4% | ||
| Q1 24 | -101.9% | -16.7% |
| Q4 25 | -299.9% | -5.1% | ||
| Q3 25 | -75.2% | -8.0% | ||
| Q2 25 | -98.2% | -4.4% | ||
| Q1 25 | -78.2% | -11.8% | ||
| Q4 24 | -100.8% | -3.8% | ||
| Q3 24 | -82.7% | -11.7% | ||
| Q2 24 | 55.6% | -27.4% | ||
| Q1 24 | -112.8% | -29.4% |
| Q4 25 | $-7.02 | $-0.11 | ||
| Q3 25 | $-3.82 | $-0.18 | ||
| Q2 25 | $-4.32 | $-0.12 | ||
| Q1 25 | $-2.77 | $-0.21 | ||
| Q4 24 | $-2.33 | $-0.11 | ||
| Q3 24 | $-3.85 | $-0.31 | ||
| Q2 24 | $-2.97 | $-0.57 | ||
| Q1 24 | $-4.85 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $-292.9M | $-18.2M |
| Total Assets | $108.4M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $10.5M | ||
| Q3 25 | $37.7M | $8.1M | ||
| Q2 25 | $38.7M | $9.1M | ||
| Q1 25 | $38.8M | $5.9M | ||
| Q4 24 | $62.5M | $12.4M | ||
| Q3 24 | $72.8M | $10.1M | ||
| Q2 24 | $84.8M | $9.3M | ||
| Q1 24 | $30.6M | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-292.9M | $-18.2M | ||
| Q3 25 | $-269.3M | $-12.1M | ||
| Q2 25 | $-238.9M | $-7.7M | ||
| Q1 25 | $-205.9M | $-8.1M | ||
| Q4 24 | $-186.0M | $-4.4M | ||
| Q3 24 | $-159.6M | $1.6M | ||
| Q2 24 | $-132.1M | $6.5M | ||
| Q1 24 | $-169.0M | $18.0M |
| Q4 25 | $108.4M | $434.9M | ||
| Q3 25 | $96.2M | $435.2M | ||
| Q2 25 | $104.9M | $438.1M | ||
| Q1 25 | $127.7M | $441.0M | ||
| Q4 24 | $164.4M | $471.0M | ||
| Q3 24 | $189.5M | $495.7M | ||
| Q2 24 | $214.0M | $494.9M | ||
| Q1 24 | $204.5M | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $4.3M |
| Free Cash FlowOCF − Capex | — | $4.1M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $4.3M | ||
| Q3 25 | $-5.9M | $295.0K | ||
| Q2 25 | $-18.7M | $1.6M | ||
| Q1 25 | $-39.0M | $-7.7M | ||
| Q4 24 | $-25.8M | $8.0M | ||
| Q3 24 | $-19.5M | $1.3M | ||
| Q2 24 | $-38.5M | $-10.4M | ||
| Q1 24 | $-43.7M | $-2.8M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $-246.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | $-25.9M | $7.0M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | $-43.9M | $-4.7M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | -84.7% | 12.0% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | -132.6% | -10.4% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.6% | 4.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
